Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.05 and last traded at C$0.06, with a volume of 40000 shares trading hands. The stock had previously closed at C$0.06.
Hemostemix Stock Performance
The firm has a market cap of C$4.94 million, a price-to-earnings ratio of -1.38 and a beta of 0.55. The stock’s 50 day simple moving average is C$0.07 and its 200-day simple moving average is C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Recommended Stories
- Five stocks we like better than Hemostemix
- The Most Important Warren Buffett Stock for Investors: His Own
- Silicon Motion Proves That AI in Motion Stays in Motion
- Canadian Penny Stocks: Can They Make You Rich?
- Undervalued UnitedHealth Group Won’t Be For Long
- How to Calculate Options Profits
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
